MedTrace Logo

COVID-19 and Nonalcoholic Fatty Liver Disease

NCT04982328 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2023-08-30

No results posted yet for this study

Summary

COVID-19 is currently the leading public health problem, associated with a high risk of complications and death in risk groups of patients. Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease with a prevalence of 30% in the Western population and is also recognized as an independent risk factor for the development of severe COVID-19. In the pathogenesis of COVID-19, the key role is played by the hyperreactivity of the immune response, the so-called cytokine storm leading to the development of severe forms of pneumonia, acute respiratory and multiorgan failure. The aim of this study is to investigate the clinical course, outcomes, and profile of inflammatory response in patients with COVID-19 and NAFLD.

Conditions

  • Covid19
  • NAFLD

Interventions

DIAGNOSTIC_TEST

Th17 cytokine profile

Screening for the components of metabolic syndrome

DIAGNOSTIC_TEST

Screening for the components of metabolic syndrome

Anthropometric measures including height, weight, waist circumference and hip circumference will be measured in all patients. Results of the routine laboratory tests as part of the standard diagnostic procedure will be collected: CRP, leukocyte count, ratio neutrophils and lymphocytes, hemoglobin, platelet count, urea, creatinine, bilirubin, AST, ALT, GGT, ALP, albumins, fasting glucose.

DIAGNOSTIC_TEST

Evaluation of the degree of steatosis

The degree of steatosis will be estimated using the ultrasound and a method for grading steatosis will be measuring the degree of ultrasound attenuation by hepatic fat using a process based on simultaneous transient elastography (TE) which measures the degree of steatosis.

Sponsors & Collaborators

  • University Hospital for Infectious Diseases, Croatia

    lead OTHER

Principal Investigators

  • Neven Papic, MD, PhD · School of Medicine, University of Zagreb, Croatia

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2021-12-31
Completion
2022-12-15

Countries

  • Croatia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04982328 on ClinicalTrials.gov